Work Here?
Overview
PacBio designs long-read DNA sequencing systems that help researchers read complete genomes, transcriptomes, and epigenomes. Its Revio and Vega platforms use proprietary HiFi sequencing chemistry, combining the completeness of long reads with the accuracy of short reads, supported by library prep kits, reagents, and the SMRT Link software suite. Specialized tools such as Kinnex for full-length RNA sequencing and PureTarget for targeted enrichment extend the platform into human genomics, oncology, microbial, agricultural, and biopharma research. What sets PacBio apart is its focus on accuracy and completeness over raw throughput, giving scientists confidence in genomic regions that short-read technologies often miss. The goal is to enable the promise of genomics to advance human health.
About PacBio
Industries
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
N/A
Simplify's Take
What believers are saying
- SPRQ-Nx started worldwide shipping May 26, and one-third of installed base opted in by June.
- Q2 2026 consumables rose 6% to $20.1 million, led by clinical shipments up 67%.
- Vega gains SPRQ-Nx in August 2026, expanding output from 60 Gb to 90 Gb.
What critics are saying
- Q2 2026 revenue fell 2% to $39 million, missing estimates and breaking momentum.
- Management cut 2026 revenue guidance to $155-$165 million and pushed cash breakeven to 2028.
- If SPRQ-Nx stalls, PacBio burns cash until 2028 and faces dilution or sale.
What makes PacBio unique
- PacBio's HiFi long reads and SPRQ-Nx cut Revio pricing to $345 on May 26.
- DNAstack's Feb. 24 consortium links 10,000-plus genomes across 15 countries without centralizing data.
- GenomOncology's July 30 workflow turns PacBio WGS outputs into clinician-ready oncology reports.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Company News
Pacific Biosciences of California reported flat Q2 2026 revenue of $39 million whilst announcing a leadership change and revised outlook. CEO Christian Henry stepped down, with Mark Van Oene taking over immediately. Consumables revenue grew 6% to $20.1 million, driven by clinical customers whose shipments jumped 67% year-over-year. However, instrument revenue fell 9% to $12.8 million due to fewer Vega shipments and lower average selling prices. The company lowered its 2026 revenue forecast to $155 million–$165 million and delayed expected cash-flow breakeven to 2028. The revised outlook reflects slower adoption of its SMRT Next chemistry, which reduces sequencing costs by 30%, as customers validate the technology and work through existing reagent inventories. PacBio does not expect a significant consumables ramp until late 2026.
GenomOncology, a precision oncology software company, has launched an integrated workflow for somatic whole-genome sequencing in oncology. The solution combines PacBio's HiFi WGS research-use-only secondary analysis pipeline with GenomOncology's Pathology Workbench platform to deliver standardised, clinician-ready reporting for clinical laboratories. The workflow addresses the challenge of translating long-read sequencing outputs into structured reports. It connects PacBio's pipeline, which handles analysis from raw sequencing through variant calls, with GenomOncology's platform for tertiary analysis, including quality control review, variant interpretation, and configurable report generation. A key feature is modular reporting architecture, enabling laboratories to derive tumour-specific sub-panels from shared WGS data whilst standardising upstream sequencing processes. The workflow can be deployed on-premises or on public cloud platforms. GenomOncology will present the workflow at the Cancer Genomics Consortium Annual Meeting in Houston from 1-5 August 2026.
PacBio has begun worldwide shipping of its SPRQ-Nx sequencing chemistry and multi-use SMRT Cells for the Revio HiFi sequencing platform. The technology brings the per genome list price to $345, with the possibility of sub-$300 genomes for customers sequencing at scale. The company has enhanced its AI capabilities through updates to DeepConsensus, an algorithm developed with Google, including optimisations from Google's AlphaEvolve coding agent. PacBio is also advancing deep learning models for epigenetic detection, including updated methylation models and a new 5-hydroxymethyl-cytosine caller. Beta testing across 20 sites involving over 1,400 runs showed increased yield and lower failure rates compared to previous SPRQ chemistry. The improvements are available on existing Revio systems through software upgrades, with plans to bring SPRQ-Nx chemistry to the Vega benchtop system later in 2026.
Pacific Biosciences of California saw its shares fall 14.2% after reporting mixed first-quarter 2026 results. The genomics company's revenue came in at $37.18 million, missing Wall Street's expectations of $40 million by over 7% and remaining flat year-on-year. While PacBio beat earnings expectations with an adjusted loss per share of $0.12 compared to the anticipated $0.13 loss, the revenue shortfall overshadowed this positive development. The company continues to face challenges including annualised revenue decline over the past two years, negative margins and significant cash burn. PacBio shares are down 24.7% year-to-date and trading at $1.39, 48.1% below their 52-week high of $2.67 from January 2026.
Pacific Biosciences of California missed Q1 CY2026 revenue expectations, reporting sales of $37.18 million versus analyst estimates of $40 million, representing a 7.1% miss and flat year-on-year performance. The genomics company's non-GAAP loss of $0.12 per share beat consensus estimates by 8.7%. CEO Christian Henry noted record consumable revenue driven by increasing clinical adoption of HiFi sequencing, but instrument revenue, particularly for Vega, fell below expectations. The company's adjusted EBITDA was -$8.17 million with a -22% margin. Despite recent struggles, with revenue declining 10.6% annually over the past two years, analysts expect 12.6% growth over the next 12 months. PacBio has a market capitalisation of $530.9 million.
PacBio is Hiring for 8 Jobs on Simplify!
Find jobs on Simplify and start your career today
About PacBio
Industries
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
N/A
PacBio is Hiring for 8 Jobs on Simplify!
Find jobs on Simplify and start your career today